Scholars have reported that EZH2 can repress multiple downstream targets (e.g., KDM6A, GIT1) directly by binding to their promoter regions contributed to the progression of urothelial bladder carcinoma (Ler et al., 2017; Yang et al., 2020). The gene discussed is EZH2; the disease is bladder transitional cell carcinoma.